Biodesix (NASDAQ:BDSX) Director Acquires $92,514.68 in Stock

Key Points

• Jack Schuler, a director at Biodesix, acquired 15,317 shares of the company's stock at an average price of $6.04 per share, increasing his position by 1.26% to a total of 1,235,644 shares.
• Biodesix reported a quarterly loss of ($1.60) EPS, missing analysts' expectations, but exceeded revenue estimates with $20.02 million in revenue.
• Research analysts show a mixed sentiment on Biodesix, with four rating it as a Buy and an average target price of $32.50, despite one recent downgrade to a "sell" rating.

Biodesix, Inc. (NASDAQ:BDSX - Get Free Report) Director Jack W. Schuler acquired 15,317 shares of the business's stock in a transaction on Wednesday, September 17th. The stock was acquired at an average price of $6.04 per share, for a total transaction of $92,514.68. Following the acquisition, the director owned 1,235,644 shares of the company's stock, valued at approximately $7,463,289.76. This trade represents a 1.26% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Biodesix Stock Up 5.9%

Shares of BDSX stock traded up $0.40 during trading hours on Friday, hitting $7.13. 244,397 shares of the company's stock traded hands, compared to its average volume of 341,148. The company has a quick ratio of 2.14, a current ratio of 2.14 and a debt-to-equity ratio of 41.11. The stock's fifty day simple moving average is $7.99 and its two-hundred day simple moving average is $8.82. Biodesix, Inc. has a 12-month low of $3.44 and a 12-month high of $37.00. The stock has a market cap of $52.26 million, a price-to-earnings ratio of -1.23 and a beta of 1.00.

Biodesix (NASDAQ:BDSX - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported ($1.60) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.40) by ($0.20). Biodesix had a negative net margin of 53.66% and a negative return on equity of 269.67%. The company had revenue of $20.02 million for the quarter, compared to analysts' expectations of $18.47 million. Biodesix has set its FY 2025 guidance at EPS. On average, analysts expect that Biodesix, Inc. will post -0.35 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the company. Canaccord Genuity Group set a $20.00 price objective on Biodesix and gave the company a "buy" rating in a research report on Friday. Wall Street Zen raised Biodesix to a "sell" rating in a report on Saturday, September 13th. Four equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $32.50.

Institutional Trading of Biodesix

Several large investors have recently modified their holdings of BDSX. Blair William & Co. IL lifted its stake in shares of Biodesix by 33.3% in the 1st quarter. Blair William & Co. IL now owns 124,100 shares of the company's stock worth $78,000 after purchasing an additional 31,000 shares during the period. Millennium Management LLC increased its holdings in Biodesix by 20.2% during the fourth quarter. Millennium Management LLC now owns 198,671 shares of the company's stock valued at $304,000 after buying an additional 33,329 shares during the last quarter. Jane Street Group LLC purchased a new stake in Biodesix during the fourth quarter valued at approximately $119,000. XTX Topco Ltd raised its position in Biodesix by 99.4% in the second quarter. XTX Topco Ltd now owns 205,647 shares of the company's stock worth $58,000 after acquiring an additional 102,494 shares during the period. Finally, Northern Trust Corp boosted its stake in shares of Biodesix by 286.5% during the 4th quarter. Northern Trust Corp now owns 169,132 shares of the company's stock worth $259,000 after acquiring an additional 125,368 shares during the last quarter. Institutional investors own 20.96% of the company's stock.

Biodesix Company Profile

Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.